A Novel, Targeted therapy for
Triple Negative Breast Cancer
and other aggressive cancers

PANNEX Therapeutics is at the forefront of developing Pannexin 1 channel (Panx1) blockers, a new class of cancer drugs that block multiple pathways to enhance the immune system’s response, curb tumor growth, and minimize the spread of metastases.

Learn more

Discover our science

Pannexin 1

The Pannexin 1 channel (Panx1), a recently discovered and validated pharmacological target, is overexpressed in many cancer types and linked to poor clinical outcome.


Our team

David Bravo PhD

Chief Executive Officer &

Pannexin 1 research leader with more than a decade of success in drug discovery and innovation

Thomas Gerlach PhD

Chief Strategic Officer &

Biochemist with over 30 years of experience in global drug development, commercialization and venture capital

Gerhard Gross PhD

Chief Scientific Officer &

Chemist with 30 years of experience in drug discovery and development - 14 FDA - approved drugs